Evidence map›Paper›PMID 41483144›Full record

ArticleJournal of gastroenterology2026

Clinical outcomes and recurrence patterns in pancreatic ductal adenocarcinoma diagnosed at an early stage: insights from a multicenter cohort study in Japan.

Juri Ikemoto, Yasutaka Ishii, Keiji Hanada, Tamito Sasaki, Yoshifumi Fujimoto, Atsushi Yamaguchi, Bunjiro Noma, Tomoyuki Minami, Masanobu Yukutake, Akihito Okazaki and 6 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Juri IkemotoDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.
Yasutaka IshiiDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan. yishii@hiroshima-u.ac.jp.ORCID 0000-0003-3545-8743
Keiji HanadaDepartment of Gastroenterology, Onomichi General Hospital, 1-10-23 Hirahara, Onomichi-Shi, Hiroshima, 722-8508, Japan.
Tamito SasakiDepartment of Gastroenterology, Hiroshima Prefectural Hospital, 1-5-54 Ujinakanda, Minami-Ku, Hiroshima-Shi, Hiroshima, 734-8530, Japan.
Yoshifumi FujimotoDepartment of Gastroenterology, Hiroshima General Hospital, 1-3-3 Jigozen, Hatsukaichi-Shi, Hiroshima, 738-8503, Japan.
Atsushi YamaguchiDepartment of Gastroenterology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, 3-1, Aoyama-Cho, Kure-Shi, Hiroshima, 737-0023, Japan.
Bunjiro NomaDepartment of Gastroenterology, Kure Kyosai Hospital, 2-3-28 Nishichuou, Kure-Shi, Hiroshima, 737-8505, Japan.
Tomoyuki MinamiDepartment of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, 1-9-6 Sendamachi, Naka-Ku, Hiroshima-Shi, Hiroshima, 730-8619, Japan.
Masanobu YukutakeDepartment of Gastroenterology, Hiroshima City North Medical Center Asa Citizens Hospital, 2-1-1 Kabeminami, Asakita-Ku, Hiroshima-Shi, Hiroshima, 731-0293, Japan.
Akihito OkazakiDepartment of Gastroenterology, National Hospital Organization Higashihiroshima Medical Center, Hiroshima, 513 Saijou-Cho Jike, Higashihiroshima-Shi, Hiroshima, 739-0041, Japan.
Teruo MouriDepartment of Gastroenterology, Chugoku Rosai Hospital, 1-5-1 Hirotagaya, Kure-Shi, Hiroshima, 737-0193, Japan.
Shinya NakamuraDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.
Kenichiro UemuraDepartment of Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima-Shi, Hiroshima, 734-8551, Japan.
Shinya TakahashiDepartment of Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima-Shi, Hiroshima, 734-8551, Japan.
Koji ArihiroDepartment of Anatomical Pathology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-Ku, Hiroshima-Shi, Hiroshima, 734-8551, Japan.
Shiro OkaDepartment of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognosis and recurrence patterns of early-diagnosed pancreatic ductal adenocarcinoma (PDAC), particularly following surgical resection, remain unclear.

methodsThis multicenter retrospective study analyzed patients who underwent surgical resection for PDAC between 2005 and 2023. Patients were categorized according to pathological stages 0, I, and II. Recurrence patterns and survival outcomes were compared among the three groups. Multivariate analysis was performed to identify independent risk factors for remnant pancreatic recurrence, including early-stage disease, postoperative follow-up of more than 5 years, and receipt of adjuvant chemotherapy.

resultsA total of 349 patients were included: 51 with stage 0, 77 with stage I, and 221 with stage II PDAC. The 5-year overall survival rates were 87%, 71%, and 49% for patients with stage 0, I, and II PDAC, respectively. Remnant pancreatic recurrence was observed in 10% of patients with stage 0 PDAC and 18% of patients with stage I PDAC, compared with 5% of those with stage II PDAC. Recurrence was significantly more frequent in stage I (P < 0.001) and tended to be higher in stage 0 (P = 0.062) than in stage II. Multivariate analysis identified pathological stage 0-I and postoperative follow-up of > 5 years as independent risk factors for remnant pancreatic recurrence.

conclusionsPatients with early-stage PDAC exhibit a higher risk of remnant pancreatic recurrence than those with stage II disease. These findings underscore the importance of long-term pancreas-focused surveillance in early-stage PDAC to enable timely detection of late recurrence and potentially improve patients outcomes.

Indexed as

Carcinoma, Pancreatic DuctalNeoplasm Recurrence, LocalPancreatic NeoplasmsAdultAgedAged, 80 and overChemotherapy, AdjuvantCohort StudiesFemaleFollow-Up StudiesHumansJapanMaleMiddle AgedNeoplasm StagingPancreatectomyEarly diagnosis of pancreatic cancerPancreatic cancerRecurrenceRemnant pancreatic recurrence

Identifiers

PMID41483144
PMCPMC12987814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.